The AMR Action Fund aims to bring 2-4 new antibiotics to patients by 2030. We will work with partners to create market conditions that enable sustainable investment in the antibiotic pipeline.
The AMR Action Fund expects to invest more than US$1 billion in smaller biotech companies and provide industry expertise to support the clinical development of novel antibiotics
Strengthens and accelerates the research and development of antibiotics through investment and provision of industry resources and expertise to biotechnology companies.
Brings together a broad alliance of industry and non-industry stakeholders, including philanthropies, development banks, and multilaterals, to encourage governments to create market conditions that enable sustainable investment in the pipeline.
Created by leading pharmaceutical companies
Supported by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)
Martin BottGeneral Manager (Interim)
Martin Bott, our interim General Manager, is Vice-President Finance at Eli Lilly and Company, responsible for special projects.
During his 31 year career at Lilly, Martin has held a series of leadership roles with growing responsibilities mainly in finance, business development, and project management. Notably, he has served as the CFO of Lilly Diabetes, CFO of Global Manufacturing, led the Corporate Finance and Investment Banking group, and recently led the strategic review and resulting IPO and spin off of Lilly’s animal health division – Elanco Animal Health. Martin has lived and worked in the US, Germany, UK, and Switzerland.
He holds a Master’s Degree of International Business from the University of South Carolina and a Commercial Assistant degree from Bayer AG/Chamber of Commerce Cologne.
Silas HollandHead of External Affairs (Interim)
Silas Holland, our interim Head of External Affairs, is a Director for Global Public Policy at MSD, where he is responsible for global health policy issues related to infectious disease.
Over the past 15 years, he has worked on programs at both the community- and global-level to expand access to medicines. He joined MSD in 2016 from the Global Fund to Fight AIDS, Tuberculosis, and Malaria, where he was responsible for the sourcing of tuberculosis health products. He has also worked for the World Health Organization and Stop TB Partnership in Geneva.
He earned a BA in Biology from Duke University and has postgraduate degrees in education (Loyola Marymount University) and public health (University of Pretoria).
Ted MurphyHead of Operations (Interim)
Ted Murphy, our interim Director of Operations, is a Finance Director at Eli Lilly and Company, responsible for special projects.
Over a nearly 10-year career, Ted has worked in a variety of different roles across finance, operations, and entrepreneurship. His career at Lilly began in the finance function with roles of increasing responsibility across Manufacturing, R&D, and Treasury. Most recently, he transitioned into the operations group supporting the Immunology portfolio. He was the co-founder of Theia Medical, a medical device startup and served as an advisor to numerous early stage companies across the US and in Europe.
Ted holds a Master’s in Business Administration from Stanford Graduate School of Business and a Bachelor of Science in Economics from Purdue University.
The pharmaceutical industry is stepping up to take on the challenge of AMR
Antimicrobial resistance (AMR) poses a growing threat to public health and to the viability of health systems around the world. We need only look at the devastating impact of the COVID-19 crisis to know that now is the time to begin a global effort to combat AMR. While Lilly is not directly engaged in antimicrobial antibiotic research and development, we are supporting the AMR Action Fund to help address the challenges in bringing new antibiotics to market. The industry is doing its part to help bridge the gap in AMR research and development in the short-term, but we need policymakers to take action now to create a viable market that incentivizes future research in this crucial area.
Governments and experts have been talking about the need to tackle the public health crisis of AMR for years. But so far no action has followed the talk. Meanwhile biotech companies developing much needed new antibiotics go bankrupt because the costs of late stage R&D cannot be recouped later in sales.
Biopharmaceutical companies want to help break the gridlock and respond to this clear public health need.
In setting up the AMR Action Fund, IFPMA is proud to have benefited from collaboration with the World Health Organization, the European Investment Bank, and the Wellcome Trust.
The Fund provides a bridging solution to help biotech companies take their discoveries over the finishing line. To recreate a viable innovation ecosystem for antibiotic research, we need governments to step up too. We need reforms that acknowledge the huge value that new antibiotics bring to society and safeguard our future from the global threat of AMR.
AMR is called a “silent tsunami,” and failing to put in a place a robust plan of action to combat this global threat could result in a greater impact to humanity than the COVID-19 pandemic. Under such circumstances, it is extremely important to launch the AMR Action Fund now. SHIONOGI hopes that this Fund will help to deliver AMR therapeutics quickly and continuously to more patients by creating a new global ecosystem in the antibacterial space.
Daiichi Sankyo is keenly aware of both the threat of AMR and the importance of effective antibiotics. In recent years, the creation of new antibiotics has been challenging and characterized by low marketability, which makes it difficult for pharmaceutical companies to carry out research and development activities and reach the commercialization stage.
The AMR Action Fund will gather accumulated industry knowledge of antibiotics development and help rectify this situation. Investments in the Fund will work to accelerate the development of effective antibiotics continuously and go a long way to eventually overcoming the global AMR problem.
At Boehringer Ingelheim, we are driven by the desire to improve the life of patients. We focus our innovation to where the medical needs are the highest. We believe that the increasing threat posed by drug-resistant bacteria and fungi is one of the key areas to be addressed in advancing human health globally. At the same time, we are convinced that a broad knowledge coalition will enhance the likelihood of success. This is why we join forces with other industry partners in the new AMR Action Fund to actively contribute to researching, developing and making available much needed new treatment options to combat infectious disease.
Antimicrobial resistance (AMR) represents a global public health crisis. Novel antibiotics are urgently needed to tackle this problem. However, research and development of new antibiotics is challenging, for various scientific, regulatory and economic reasons. Roche is proud to be a partner in the AMR action fund, which addresses the existing funding gap for clinical development of new antibiotics leading up to commercialization. Together with the efforts of policymakers to implement market-based reforms, the AMR action fund will make a major contribution toward the development of a sustainable antibiotics market and ecosystem for the benefit of patients worldwide.